Sequella, Inc.
PrivateLast Round
Convertible Debt
Oct 1, 2014
Total Funding Raised
$24.38M
Company Overview
Sequella, Inc. is a biopharmaceutical company that develops novel small-molecule antibiotics to treat drug-resistant bacterial, fungal, and parasitic infections.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sequella, Inc. Comparables
Compare Sequella, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| DeNovaMed Inc. | 82% | |
| Microbiotix, Inc. | 81% | |
| Bioversys | 78% | |
Sequella, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Oct 1, 2014 | ||||
| VC Round | Aug 23, 2011 | ||||
| Strategic | Apr 26, 2011 | ||||
| Grant | Apr 4, 2011 | ||||
| Grant | Oct 28, 2010 | ||||
VC Round | Oct 4, 2007 |
Sequella, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Allergy and Infectious Diseases | Grant |
| Bundesministerium für Bildung und Forschung | Grant |
| European and Developing Countries Clinical Trials Partnership | Grant |
| Medical Research Council | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 4, 2011
$4.6M grant from the National Institute of Allergy and Infectious Diseases.
- Oct 28, 2010
$17M grant round led by European and Developing Countries Clinical Trials Partnership.
Sequella, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Sequella, Inc.'s valuation, stock price, and market status.